UK News
-
Pandemic loss of heart procedures – new estimates
As many as 45,000 heart procedures may have been missed or delayed this year in England because of the COVID-19 pandemic, according to a new analysis. Read more
-
Test identifies relapse risk among breast cancer patients
A low cost test could identify breast cancer patients who have an increased risk of relapse, according to the findings of a major clinical trial reported today. Read more
-
New details of post COVID syndrome
More details of the new “post COVID syndrome” have been announced, defining it as a condition lasting for longer than 12 weeks. Read more
-
CA125 test better at predicting ovarian cancer
A readily available blood test is able to predict ovarian cancer risk more successfully than previously thought – particularly for the over 50s, according to newly published findings. Read more
-
Hope for new psoriasis treatment
A possible new therapy for psoriasis has shown promise, a European conference has heard. Read more
-
COVID-19 antibody therapy candidates identified
UK scientists have identified a potentially ground-breaking antibody combination that could be used as a “cocktail” against COVID-19, it is revealed today. Read more
-
Breast cancer and HRT risks evaluated
New estimates of the increased risks of breast cancer associated with different hormone replacement therapy preparations in the UK are published today. Read more
-
Drug trial for Parkinson hallucinations
An anti-nausea drug is being tested to see if it can reduce the hallucinations which affect people with Parkinson’s disease. Read more
-
Vitamin D linked to respiratory disease including COVID-19
A large proportion of patients hospitalised with COVID-19 have a deficiency of vitamin D, according to a new analysis. Read more
-
India trial finds limited effectiveness from convalescent plasma
Using convalescent plasma to treat moderately ill COVID-19 patients did not reduce severity of the illness or risk of death, according to the findings of a small clinical trial published today. Read more
